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Abstract
Background: Artemether-lumefantrine is currently the most widely recommended treatment of uncomplicated
malaria. Lopinavir–based antiretroviral therapy is the commonly recommended second-line HIV treatment.
Artemether and lumefantrine are metabolised by cytochrome P450 isoenzyme CYP3A4, which lopinavir/
ritonavir inhibits, potentially causing clinically important drug-drug interactions.
Methods: An adaptive, parallel-design safety and pharmacokinetic study was conducted in HIV-infected
(malaria-negative) patients: antiretroviral-naïve and those stable on lopinavir/ritonavir-based antiretrovirals.
Both groups received the recommended six-dose artemether-lumefantrine treatment. The primary outcome
was day-7 lumefantrine concentrations, as these correlate with antimalarial efficacy. Adverse events were
solicited throughout the study, recording the onset, duration, severity, and relationship to artemether-lumefantrine.
Results: We enrolled 34 patients. Median day-7 lumefantrine concentrations were almost 10-fold higher in
the lopinavir than the antiretroviral-naïve group [3170 versus 336 ng/mL; p = 0.0001], with AUC(0-inf) and Cmax
increased five-fold [2478 versus 445 μg.h/mL; p = 0.0001], and three-fold [28.2 versus 8.8 μg/mL; p < 0.0001],
respectively. Lumefantrine Cmax, and AUC(0-inf) increased significantly with mg/kg dose in the lopinavir, but not
the antiretroviral-naïve group. While artemether exposure was similar between groups, Cmax and AUC(0-8h) of
its active metabolite dihydroartemisinin were initially two-fold higher in the lopinavir group [p = 0.004 and p = 0.0013,
respectively]. However, this difference was no longer apparent after the last artemether-lumefantrine dose. Within
21 days of starting artemether-lumefantrine there were similar numbers of treatment emergent adverse events
(42 vs. 35) and adverse reactions (12 vs. 15, p = 0.21) in the lopinavir and antiretroviral-naïve groups, respectively.
There were no serious adverse events and no difference in electrocardiographic QTcF- and PR-intervals, at the
predicted lumefantrine Tmax.
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Conclusion: Despite substantially higher lumefantrine exposure, intensive monitoring in our relatively small study
raised no safety concerns in HIV-infected patients stable on lopinavir-based antiretroviral therapy given the
recommended artemether-lumefantrine dosage. Increased day-7 lumefantrine concentrations have been shown
previously to reduce the risk of malaria treatment failure, but further evidence in adult patients co-infected
with malaria and HIV is needed to assess the artemether-lumefantrine risk : benefit profile in this vulnerable
population fully. Our antiretroviral-naïve patients confirmed previous findings that lumefantrine absorption is
almost saturated at currently recommended doses, but this dose-limited absorption was overcome in the
lopinavir group.
Trial registration: Clinical Trial Registration number NCT00869700. Registered on clinicaltrials.gov 25 March 2009
Keywords: HIV, Malaria, Artemether, Lumefantrine, Lopinavir, Ritonavir, Drug interaction, Safety, Pharmacokinetic,
Dose-related exposure
Background
With the overlapping geographic distribution of HIV
and P. falciparum malaria, many patients may require
co-treatment with antiretrovirals and antimalarials. For
uncomplicated malaria, the World Health Organization
(WHO) recommends artemisinin-based combination
therapies (ACTs), of which the fixed-dose combination
artemether-lumefantrine is currently most widely used,
accounting for 73 % of ACTs procured in 2013 [1]. The
precise pharmacokinetic determinants of treatment out-
come in uncomplicated malaria remain uncertain, but
the area under the concentration-time curve (AUC) and
the concentration on day-7 of slowly eliminated anti-
malarials are considered important predictors [2, 3].
The ‘therapeutic’ day-7 lumefantrine concentrations
published to date range between 170 ng/mL to
500 ng/mL, with a concentration of 280 ng/mL most
often cited [4–12].
As the HIV pandemic matures, increasing numbers
of patients develop resistance to first-line antiretro-
viral therapy (ART) and are placed on second-line
ART. Ritonavir-boosted lopinavir-based ART is the
most widely used second-line ART in Africa and South
East Asia. Artemether, lumefantrine and lopinavir are all
primarily metabolised by the same cytochrome P450
(CYP) iso-enzyme, CYP3A4. Ritonavir is a potent inhibi-
tor of CYP3A4 creating the potential for clinically signifi-
cant drug-drug interactions [13]. Although the interaction
between lopinavir and ritonavir is used for therapeutic
advantage, known as ‘boosting’, there is limited evidence
to inform clinicians and policy makers about the inter-
action between artemether-lumefantrine and lopinavir-
based ART, leading to inconsistent recommendations on
the use of artemether-lumefantrine in patients co-infected
with HIV/AIDS [12, 14, 15]. As access to antiretrovirals
and ACTs increase, the importance of defining the inter-
action between antimalarials and ART becomes more ur-
gent. Our study investigated the pharmacokinetics and
safety of the recommended adult dose of artemether-
lumefantrine when given to HIV-infected patients stable
on lopinavir-based ART.
Methods
Subjects and study design
We conducted a sequential, two-period, adaptive design,
open-label, pharmacokinetic and safety drug-drug inter-
action study at the Groote Schuur Hospital Clinical
Pharmacology Research Ward in Cape Town, South Africa.
HIV-infected adults (18 years of age or older) with
CD4+ lymphocyte counts greater than 200 cells/μL were
enrolled. Participants enrolled were stable on treatment
with lopinavir-based ART for a minimum of six weeks.
They were compared with a group of patients who were
antiretroviral (ARV)-naïve and not yet eligible for ART,
according to the South African National HIV Treatment
Guidelines at the time [16, 17]. The participants were
otherwise well adults without renal disease and were not
geriatric, underweight, overweight or obese [18].
Exclusion criteria for safety reasons were a current
diagnosis of malaria, known hypersensitivity to arte-
mether or lumefantrine, pregnancy (as confirmed by a
serum Beta-HCG test), breast-feeding, or clinically rele-
vant hepatic or renal dysfunction. In addition, those
with a pre-existing (or family history of ) prolonged QT
interval, cardiac dysrhythmia, electrolyte disturbances
or taking any drugs known to prolong the QT interval,
were excluded. Exclusion criteria for potential con-
founding of the pharmacokinetic parameters included
participants using other drugs known to interact via the
CYP450 enzyme system, current smokers, or alcohol
users who would not abstain from alcohol intake for
the trial duration. Caffeine, grapefruit juice or strenu-
ous exercises were not permitted from 24 h before and
during study admission.
Ethics, consent and permissions
Patients provided written informed consent prior to
enrollment. Regulatory approval was received from
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the University of Cape Town Research Ethics Committee
and the South African Medicines Control Council
(Clinical Trial Registration number NCT00869700).
The procedures followed were in accordance with the
Good Clinical Practice Guidelines, including the
Helsinki Declaration of 1975, as revised in 2008.
Dosing and pharmacokinetic sample collection
As there was a safety concern about increases in
lumefantrine concentrations secondary to inhibition
by ritonavir and lopinavir, patients on lopinavir-based
treatment were admitted for a single dose of
artemether-lumefantrine (80 mg/480 mg) in a dose-
finding safety phase. Pharmacokinetic and safety re-
sults were analysed and reviewed by the Data Safety
Monitoring Board prior to approval of the adapted
dose used in the multiple-dosing phase. The ARV-naïve
participants took part in the multiple-dosing phase
only, when the recommended adult 80 mg/480 mg
artemether-lumefantrine dose was given at 0, 8, 24,
36, 48 and 60 h [12] .
In both study groups, all doses were administered with
40 mL of soya milk (0.8 g fat) and a meal containing a
minimum of 6 g of fat within one hour of each dose,
with the exception of dose 2 (at 8 h) when only soya
milk accompanied the dose.
Participants were admitted for rich pharmacokinetic
sampling (until 72 h after the first artemether-
lumefantrine dose). Subsequent samples were collected
on an outpatient basis until day 21. Venous blood sam-
ples were collected into heparinised (LH PST II) BD
Vacutainer® tubes. The blood tubes were pre-chilled on
ice for 10 min; all samples were again chilled before
being centrifuged at 4 °C for 10 min at 2000 g. The
resulting plasma was stored at −80 °C within 30 min of
the blood draw. Pharmacokinetic assays were done
within four months of sample collection.
For the Phase 1 (single-dose) pharmacokinetic profile:
Plasma concentrations of lumefantrine were assayed at
pre-dose (0 h), 0.5,1, 1.5, 2, 3, 4, 5, 6, 8, 14, 24, 36, 48,
60, 72, 96, 120, 144, 168, 336 and 504 h post and arte-
mether/dihydroartemisinin concentrations were assayed
at pre-dose (0 h), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, and 24 h
after the first artemether-lumefantrine dose.
For the Phase 2 (full-treatment dose) pharmacoki-
netic profile: Plasma concentrations of lumefantrine
were assayed at pre-dose (0 h), 0.5,1, 1.5, 2, 3, 4, 5,
6, 8, 14, 24, 30, 36, 42, 48, 54, 60, 61.5, 62, 63, 64,
65, 66, 68, 70, 72, 96, 120, 144, 168, 336 and 504 h,
and artemether/dihydroartemisinin concentrations were
assayed at pre-dose (0 h), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8,
24, 60, 61.5, 62, 63, 64, 65, 66, 68, 70 and 72 h post-
dose.
Pharmacokinetic assays
Concentrations of lumefantrine, artemether, and dihy-
droartemisinin were determined by the Division of
Clinical Pharmacology Laboratory, University of Cape
Town using validated liquid chromatography tandem
mass spectrometer (LC-MS/MS) assays as described
previously [16].
Safety data collection
A clinical evaluation and full-blood count, renal function
tests, liver enzymes, lactate and glucose blood tests were
performed at screening and at the final safety visit
21 days after the first artemether-lumefantrine dose in
both the single-dose and multiple-dose phases of the
study. CD4+ lymphocyte counts and HIV-1 viral loads
and serum pregnancy tests (in all women) as well as
urine tests for drugs of abuse (amphetamines, benzodi-
azepines and opiates) were performed at screening.
Twelve-lead single electrocardiograms (ECGs) were per-
formed at screening, pre-dose and at the expected time
of maximal lumefantrine plasma concentration (68 h
post-dose) [19]. An independent cardiologist assessed all
ECGs and the QT interval was corrected using the
Fridericia formula [20]. Adverse events were solicited
throughout the study, starting on completion of
screening and recording the onset, duration, severity,
relationship to study drug and need for treatment
[21, 22]. These were classified using MedDRA pre-
ferred terms. Some participants in the lopinavir group
were also included in a methods sub-study evaluating
more intensive methods for eliciting adverse event
data from participants including checklists, in-depth
interviews and focus group discussions [22].
Statistical methods
The sample size was calculated to demonstrate a 2-fold
change in lumefantrine exposure (day 7 concentration or
AUC), i.e., such that the 90 % confidence intervals (CIs)
for geometric mean ratios lie outside the interval 0.5 to
2.0 with a power of 80 % [19]. Thirteen participants were
required in each group and a total of 18 participants
were recruited for each arm to accommodate potential
dropouts [16].
Data analysis and pharmacokinetic modelling (non-
compartmental) were performed using Stata 13 (Stata-
Corp, College Station, Texas). Concentrations below
the limits of quantification were considered missing.
Area under the concentration-time curve (AUC0-∞)
was calculated using the trapezoidal rule. Elimination
half-life was calculated as ln(2) ⁄ λz, where λz is the
first order rate constant associated with the terminal
(log-linear) portion of the curve, estimated by linear
regression of time vs. log concentration, using the de-
fault of last three data points.
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In order to predict a safe dose for administration
in Phase 2, the lumefantrine concentration-time data
(0–8 h) from our single-dose safety phase (Phase 1)
were compared with those in 18 ARV-naïve subjects
included in our prior antimalarial-antiretroviral drug
interaction study using geometric mean ratios [16].
In the latter study the subjects completed a full
course of artemether-lumefantrine using the same
schedule as in the multiple-dose phase.
Determinants of lumefantrine day-7 concentrations,
AUC(0-inf ) and Cmax values were explored using linear
regression of the log transformed values, with results re-
ported as geometric mean ratios (GMR). The Spearman
rank correlation test was used to test the correlation be-
tween lumefantrine day-7 concentrations and AUC(0-inf ).
Logistic regression was used to explore the determinants
of day-7 lumefantrine concentrations below the reported
therapeutic concentration (280 ng/mL). Continuous and
categorical covariates were compared between groups at
baseline using Kruskal-Wallis and Chi-squared tests,
respectively. Kruskall Wallis tests were also used for
simple comparisons of the day-7 lumefantrine concen-
trations, AUC and Cmax values between groups. In order
to account for the repeated measures per subject, par-
ticularly given previously reported auto-induction effects
with the artemisinins, mixed-effect regression models
were used to assess the possible impact of dose-occasion
on artemether and dihydroartemisinin exposure, where
the responses were log-transformed AUC and Cmax
values.
Secondary safety endpoints included frequency and se-
verity of adverse events, changes in haematological, serum
biochemical and urinalysis parameters, and vital signs be-
tween screening and follow-up. The risk of adverse drug
reactions was compared between treatment groups using
logistic regression. ECG parameters (PR-, QRS-, RR- and
QT-intervals) were compared within groups between
screening and the predicted lumefantrine Tmax using the
Wilcoxon signed rank test, while the Wilcoxon rank sum
test was used to compare these between groups and
within period, and their correlation with lumefantrine
concentrations was assessed using the Spearman Rank
correlation test.
Results
Study population
Thirty-six adults (18 in the ARV-naïve group and 18 in
the lopinavir group) were recruited. All 18 in the ARV-
naïve group and 16/18 (89 %) in the lopinavir group
completed the study. One participant was replaced after
being excluded prior to Phase 2 dosing due to starting a
potentially interacting medication (amitriptyline); two
participants withdrew consent during phase 2 (one to at-
tend a funeral in another province, the other provided
no explanation). At baseline, the groups were well
matched for weight-adjusted (mg/kg) lumefantrine
dose and CD4+ lymphocyte count. ARV-naïve pa-
tients were younger (p = 0.0001), and had a higher
median viral load (3.76 log10 copies/mL; p = 0.0005).
The mean corpuscular volume was higher with ARV
use, as is expected with AZT and d4T. Gamma
glutamyl-transferase levels were higher in the lopina-
vir group than the ARV-naïve group (median 26 (IQR
18–44) U/L vs. 15 (13–29) U/L; p = 0.03), which re-
flects the higher upper limit of the normal range in
males than females (60 vs. 35 U/L); males made up
6 % of the ARV-naïve group and 31 % of the lopina-
vir group. Six participants in the ARV-naïve group
and five in the lopinavir group (p = 1.0) were receiv-
ing cotrimoxazole prophylaxis (Table 1).
Pharmacokinetic results
Single-dose safety phase (Phase 1)
The non-compartmental analysis of the single artemether-
lumefantrine dose, safety phase (Phase 1) in the lopinavir
group was compared with the ARV-naïve group. The
GMR (90 % CI) for the lumefantrine Cmax was 1.86
(1.48–2.33), while that for the lumefantrine AUC(0-8h)
was 1.78 (1.43–2.33). The Data Safety Monitoring
Board and investigators agreed based on the prede-
fined criteria (i.e., GMR between 0.5 and 2) to con-
tinuing to Phase 2 using the full recommended adult
six-dose artemether-lumefantrine regimen.
Effect of lopinavir-based ART on lumefantrine plasma
concentrations following six-dose artemether-lumefantrine
regimen (Phase 2)
The lumefantrine plasma concentration-time curves
(0–504 hours) are depicted in Fig. 1 and summarised
in Table 2. Median lumefantrine maximum (Cmax)
concentrations of 8.76 and 28.15 μg/mL were
achieved at a median time (Tmax) of 42 and 67 h
respectively in the ARV-naïve and lopinavir groups.
The median area under the plasma lumefantrine con-
centration time curve (AUC(0-inf )) was 2478 μg.h/mL
in the lopinavir group and 445 μg.h/mL in the ARV-
naïve group (p = 0.0001). Elimination half-life also
appeared longer in the lopinavir group (4.6 vs 4.1 h,
p = 0.0027), although this is more likely to reflect im-
proved bioavailability with lopinavir co-administration.
Median (range) day-7 lumefantrine concentrations
were 3170 (772–18,100) ng/mL in the lopinavir group
compared to 336 (29–934) ng/mL in the ARV-naïve
group (p = 0.0001). Across both groups, each 1 mg/kg
increase in the lumefantrine dose increased day-7 lume-
fantrine concentrations by 5.9 % (95 % CI 2.1–9.8 %; p =
0.003). After adjusting for mg/kg dose, the lumefantrine
day-7 concentration for the lopinavir group was 10-fold
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those in the ARV-naïve group (adjusted GMR 10.4 [95 %
CI 6.4–16.9]; p < 0.0001). None of the subjects in the
lopinavir group had day-7 lumefantrine concentrations
below a therapeutic threshold (280 ng/mL), compared
to one-third (6/18) of those in the ARV-naïve group (p
= 0.02). Lumefantrine day-7 concentrations and AUC(0-
inf ) were highly correlated (R-squared = 0.98).
Adjusting for mg/kg dose (the only significant co-
variate), the median lumefantrine AUC(0-inf ) was al-
most five-fold higher (GMR 4.82 95 % CI 3.41–6.79,
p < 0.0001) and the median Cmax values more than
doubled (GMR 2.67 95 % CI 1.99–3.59; p < 0.0001) in
the lopinavir than the ARV-naïve group. However, the
increase in exposure with mg/kg dose was only seen
in the lopinavir group in whom the Cmax increased by
4.8 % (95%CI 0.9–8.6 %; p = 0.019) and the AUC(0-inf )
increased by 5.4 % (95%CI 0.7–10.0 %; p = 0.026), re-
spectively with each 1 mg/kg increase in lumefantrine
dose (Fig. 2).
Effect of lopinavir-based ART on artemether and
dihydroartemisinin plasma concentrations following
six-dose artemether-lumefantrine regimen (Phase 2)
The artemether and dihydroartemisinin plasma con-
centration-time curves after artemether-lumefantrine dose
one (0–8 hours) and dose six (60–68 hours) are depicted
in Fig. 3, with artemether and dihydroartemisinin pharma-
cokinetic parameters summarised by treatment group in
Table 3.
For artemether, there were no significant differences
between treatment groups for any of the pharmacoki-
netic parameters at either of the time periods studied, 0
to 8 h and 60 to 68 h (Table 3). However, the mixed-
effect model showed a significant dose-occasion effect
on the artemether AUC and Cmax in both treatment
groups. After the last artemether-lumefantrine dose
(60–68 hours), artemether Cmax was 76 % lower
(GMR 0.24 [95 % CI 0.17–0.34]) and AUC was 58 %
lower (GMR 0.42 [95 % CI 0.30–0.59]; p < 0.0001)
than after the first artemether-lumefantrine dose.
For dihydroartemisinin, after dose 1 (0 to 8 h), the lopi-
navir group had almost double the exposure of the ARV-
naïve group (median [range] Cmax of 77.5 [30.3–189.0] vs.
42.2 [17.4–94.4] ng/mL; p = 0.004) and AUC(0-8h) of 283.6
[110.1–495.6] vs. 123.8 [79.7–340.0] ng.h/mL; p = 0.001).
By 60 to 68 h (after dose 6), exposure was similar between
treatment groups other than slight differences in the
Fig. 1 Scatter plot of Plasma lumefantrine concentrations over time,
by study group
Table 1 Baseline characteristics in HIV-1 infected patients who are antiretroviral-naïve (n = 18) or on lopinavir-based antiretroviral
therapy (n = 16)
Parameter ARV-Naïve group Lopinavir group p value
Sex female n (%) 17 (94 %) 11 (69 %) 0.078
Age (years) 27 (25–32) 37 (33–41) <0.0001
Total lumefantrine dose (mg/kg) 49.7 (43.0–52.4) 46.5 (41.4–51.9) 0.72
Weight (kg) 58 (55–67) 62 (56–70) 0.72
Albumin (g/L) 40 (39–44) 43 (41.5–44) 0.14
Alkaline phosphatase (U/L) 57.5 (50–69) 69.5 (59–88) 0.09
Gamma glutamyltransferase (U/L) 40 (39–44) 43 (42–44) 0.03
Alanine transaminase (U/L) 15 (13–29) 26 (18–44) 0.72
Aspartate transaminase (U/L) 22 (14–28) 19 (17–30) 0.59
Mean corpuscular volume (fL) 86.7 (85–91) 100.95 (98–110) 0.0001
Concomitant cotrimoxazole n (%) 6 (33 %) 5 (31 %) 1.0
CD4+ count (×106/L) 356 (260–507) 375 (296–590) 0.7
HIV viral load (copies/mL) log10 3.76 (3.0–4.1) <50 copies/μL 0.0005
Values are shown as medians (interquartile ranges [IQRs]) or n (%). Statistical significance (p values) calculated using the Kruskal-Wallis test or chi-squared test,
as appropriate
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elimination half-life (Table 3, Figs. 3 and 4). These findings
were confirmed in the mixed-effect model, which also
showed that the dihydroartemisinin AUC increased sig-
nificantly between the first and last dose in the ARV-naïve
group (GMR 1.30 [95 % CI 1.03–1.64], p = 0.03) but not in
the lopinavir group (p = 0.195) (Table 4).
Electrocardiograph safety
The QTcF intervals were similar between treatment
groups at the predicted time to maximum concentration
(~Tmax, 68 h after the first dose, which was very close
to the observed Cmax of 67 h in the lopinavir group)
and within groups between screening and ~ Tmax. There
were no QTcF intervals > 450 msec, even at ~ Tmax.
The median (range) QTcF intervals were 406 (370–443)
ms at ~ Tmax in the lopinavir group, compared with
409 (366–436) ms in the ARV-naïve group (p = 0.72) at
68 h, and 408 (370–438) ms in the lopinavir group at
screening (p = 0.89). PR intervals were not prolonged in
any participant, but did increase slightly in both groups
between screening and ~ Tmax (mean from 161 to
168 ms in ARV-naïve group (p = 0.027) and from 152
to 166 ms in the lopinavir group (p = 0.012). However,
PR intervals were similar between treatment groups
at screening (p = 0.41) and ~ Tmax (p = 0.62). Lume-
fantrine concentrations at ~ Tmax were not associ-
ated with QTcF (p = 0.54) or PR intervals (p = 0.12).
Adverse events
There were 173 adverse events recorded overall, with no
serious or severe adverse events. All patients except one
in the ARV-naive group experienced at least one adverse
event. Within 21 days of starting the full (6-dose)
artemether-lumefantrine treatment there were 42 ad-
verse events occurring in the lopinavir group (n = 16)
and 35 adverse events in the ARV-naïve group (n = 18)
Table 2 Lumefantrine pharmacokinetic parameters following six-dose artemether-lumefantrine treatment in HIV-1 infected patients
who are antiretroviral-naïve or on lopinavir-based antiretroviral therapy
Parameter median (IQR) ARV-naïve group (n = 18) Lopinavir group (n = 16) p value
Cmax (μg/mL) 8.76 (7.80–9.84) 28.15 (14.00–32.95) <0.0001
CV 26.3 % 59.6 %
Tmax (h) 42 (42–66) 67 (51–70) 0.031
CV 35.5 % 27.1 %
AUC(0-inf) (μg.h/mL) 445 (357–553) 2478 (1093–3596) <0.0001
CV 33.5 % 71.0 %
T1/2 (days) 4.1 (2.7–4.4) 4.6 (4.4–5.2) 0.003
CV 25.7 % 15.4 %
Day-7 conc (ng/mL) 336 (230–396) 3170 (1440–5085) <0.0001
CV 54.0 % 98.5 %
Values are shown as medians (interquartile ranges [IQRs]) and Coefficient of variation (CV, %). Cmax, maximal concentration; Tmax, time at the maximal
concentration; AUC(0-inf), area under the plasma concentration-time curve, from 0 h to infinity; t1/2, elimination half-life; Day-7 concentration, lumefantrine
concentration on day-7;. Statistical significance (p values) calculated using the Kruskal-Wallis test
Fig. 2 Scatter plot showing the effect of mg/kg lumefantrine
dose (given twice daily for three days) on a lumefantrine
maximum concentration (upper panel) and b lumefantrine area
under the concentration time curve (AUC(0-inf)) (lower panel), by
treatment group
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[Table 5]. Of these adverse events, 27 were considered
possibly related to study drug, 15 and 12 in the ARV-
naïve and lopinavir groups, respectively (p = 0.21). Most
events were classified as mild, and all four of the mode-
rate adverse events were not considered related to
artemether-lumefantrine. The most common adverse
events considered possibly related to artemether-
lumefantrine were: headache (n = 7, with 4 in ARV-naïve
group and 3 in lopinavir group), nausea (n = 5, with 3 in
ARV-naïve group and 2 in lopinavir group), diarrhoea
(n = 3, with 1 in ARV-naïve group and 2 in lopinavir
group), and flatulence (n = 3, all in ARV-naïve group).
Among those in the lopinavir group given a single dose
of artemether-lumefantrine during Phase 1 (n = 18),
there were 37 treatment emergent adverse events, seven
of which were considered possibly related to artemether-
lumefantrine (Additional file 1), with a trend (p = 0.095)
towards fewer adverse reactions than in those given the
full 6-dose artemether-lumefantrine treatment, regard-
less of the antiretroviral regimen used. A further 11 AEs
were reported before the artemether-lumefantrine dose
was administered, and another 27 after 21 days of follow
up (mostly between the single and multiple artemether-
lumefantrine dose phases in the lopinavir group). Another
Fig. 3 Scatter plot of Plasma artemether (ART) and dihydroartemisinin (DHA) concentrations over time, by study group and treatment period
(after dose 1 (0–8 hours), and after dose 6 (60–68 hours))
Table 3 Artemether and dihydroartemisinin pharmacokinetic parameters in HIV-1 infected patients who are antiretroviral (ARV)-naïve
or on lopinavir-based antiretroviral therapy (ART), after artemether-lumefantrine dose 1 (0–8 hours) and dose 6 (60–68 hours)
0–8 hours 60–68 hours
ARV-Naïve group Lopinavir group p value ARV-Naïve group Lopinavir group p value
Artemether
Cmax (ng/mL) 59.7 (37.8–88.9) 85.8 (39.7–145) 0. 16 11.9 (8.2–17.5) 16.5 (7.2–50.5) 0.35
Tmax (h) 1.5 (1.5–2.0) 1.8 (1.5–3.0) 0. 97 61.5 (61.5–62.0) 61.5 (61.5–62.0) 0. 84
AUC(0-inf) (ng.h/mL) 151.0 (110.7–220.6) 220.0 (113.9–431.2) 0.17 71.1 (45.5–114.2) 93.8 (37.5–219.1) 0. 37
t1/2 (hr) 1.5 (1.1–1.7) 1.4 (0.9–1.6) 0. 39 2.9 (1.8–5.4) 3.0 (1.9–3.4) 0. 68
Dihydroartemisinin
Cmax (ng/mL) 42.2 (31.8–63.1) 77.5 (59.4–102) 0.004 40.0 (31.2–66.7) 65.8 (38.2–92.7) 0.21
Tmax (h) 2.0 (1.5–4.0) 2.0 (1.5–3.0) 0.41 61.5 (61.5–62.0) 61.6 (61.5–62.5) 0.71
AUC(0-inf) (ng.h/mL) 123.8 (101.3–235.6) 283.6 (178.1–340.7) 0.001 165.7 (143.7–246.5) 243.5 (145.1–305.0) 0.27
T1/2 (h) 1.6 (1.3–2.1) 1.4 (1.1–1.6) 0. 07 2.0 (1.8–2.7) 1.8 (1.5–2.0) 0. 02
Values are reported as median (interquartile range [IQR]). Cmax, maximal concentration; Tmax, time at the maximal concentration; AUC (0-inf), area under the
plasma concentration-time curve, from 0 h to infinity; t1/2, elimination half-life. Statistical significance (p values) calculated using the Kruskal-Wallis test
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21 adverse events were detected in a methods sub-study
with more intensive enquiry about adverse events using
checklists, in depth interviews and focus group discus-
sions only conducted in some participants in the lopinavir
group [22].
Discussion
We investigated the safety and pharmacokinetics of
artemether-lumefantrine after the recommended six-dose
regimen in HIV-infected adult patients, comparing
results in ARV-naïve patients with those on lopinavir-
based antiretroviral therapy. We found that those on
antiretroviral therapy had a 10-fold increase in their
day-7 lumefantrine concentrations, with an almost
five-fold increase in their lumefantrine AUC(0-inf ) and
almost three-fold increase in the maximum lumefan-
trine concentration. Despite this substantially elevated
exposure, detailed assessments for clinical, haemato-
logical, biochemical or electrocardiographic adverse
events raised no safety concerns associated with con-
comitant artemether-lumefantrine and lopinavir-based
ART administration. There were no serious adverse
events, and most adverse events were mild in intensity.
Within 21 days of starting artemether-lumefantrine there
were similar numbers of treatment emergent adverse
events (42 vs. 35) and adverse reactions (12 vs. 15) in the
lopinavir and ARV-naïve groups, respectively.
Lumefantrine is chemically similar to halofantrine,
which is known to cause significant QT prolongation
and cardiac arrhythmias even at standard doses. This
structural similarity initially raised the concern of po-
tential cardiac toxicity, but this was not confirmed in
a prospective study [23]. The electrocardiographic as-
sessments in the lopinavir group, including those at
the time of predicted maximal lumefantrine concen-
tration, did not show prolonged PR or QTcF intervals,
and were not significantly different from the intervals
found in the ARV-naïve group. This is consistent with
findings by Byakika-Kibwika et al. who assessed cardiac
conduction safety in HIV-positive adults, and found that
QTc intervals remained well within the normal limits over
the 72 h after a single artemether-lumefantrine dose,
although the mean QTc interval after AL administration
was longer in the lopinavir arm compared to the ARV-
naïve arm [24].
Although artemether pharmacokinetic parameters
were not significantly different between treatment
groups in either period, we found a significant dose-
occasion effect with five-fold decreases in artemether
maximal concentrations, and more than two-fold
decreases in AUC between the first and last dose. This is
expected given the auto-induction previously described
with the artemisinins [16, 25–28]. The dihydroartemisinin
Fig. 4 Box plot of area under the plasma artemether (ART, upper
panel) and dihydroartemisinin (DHA, lower panel) concentration
time curves (0-infinity) ng.h/mL after artemether-lumefantrine dose 1
(0–8 hours) and dose 6 (60–68 hours), by study group
Table 4 Mixed-effects model of the effects of dose occasion, treatment group and covariates on dihydroartemisinin exposure in
HIV-1 infected patients
Dose occasion effect (last/first dose occasion) AUC GMR (95 % CI) Cmax GMR (95 % CI)
- Antiretroviral naïve group 1.30 (1.03–1.64) 1.12 (0.84–1.49)
- Lopinavir group 0.84 (0.65–1.09) 0.77 (0.56–1.05)
Treatment group effect (lopinavir group/naïve group)
- 0 to 8 h 1.73 (1.26–2.37) 1.73 (1.24–2.43)
- 60 to 68 h 1.12 (0.56–1.55) 1.19 (0.58–2.57)
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Table 5 Treatment Emergent Adverse Events by treament group, causality and intensity
ARV naïve group (n=18) Lopinavir group (n=16)
AL suspected AL not suspected AL suspected AL not suspected
Mild Moderate Mild Moderate Mild Moderate Mild Moderate
Gastrointestinal disorders
Abdominal pain 1
Constipation 1
Decreased appetite 1 1
Diarrhoea 1 1 2 1
Dyspepsia 2
Epigastric discomfort 1 1
Flatulence 3
Gastrooesophageal reflux disease 1
Nausea 3 2
Vomiting 2
Infections and infestations
Gingivitis 1
Influenza-like illness 3 2
Nervous system disorders
Dizziness 1 1
Headache 4 3 1 3 2
Presyncope 1
Respiratory, thoracic and mediastinal disorders
Nasal congestion 1
Rhinorrhoea 1
Skin and subcutaneous tissue disorders
Abscess 1
Body tinea 1
Rash 1 1
Seborrhoeic dermatitis 1
General disorders and administration site conditions
Fatigue 1 1
Injection site reaction 2 3
Musculoskeletal and connective tissue disorders
Back / neck pain 3
Muscle twitching 2
Renal and urinary disorders
Frequency of micturition 1
Urinary tract infection 1 1
Reproductive system and breast disorders
Vaginal discharge 1
Immune system disorders
Seasonal allergy 1
Vascular disorders
Epistaxis 1
Hypertension 1 1
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maximal concentration and exposure were almost double
in the lopinavir group compared to the ARV-naïve group
at 0 to 8 h, although these were similar between treatment
groups after the last dose. Artemether and dihydroartemi-
sinin exposure in our ARV-naïve group were similar to
the results from previously published healthy volunteer
studies, suggesting that there is not a marked HIV disease
effect [19, 29]. Unlike the findings in a single artemether-
lumefantrine dose study in HIV-infected Ugandan adults
[30], our dihydroartemisinin concentrations were higher
in the lopinavir group at 0–8 hours, which was also
reported by German et al. in healthy volunteers [29].
If confirmed, this increased artemisinin exposure with
lopinavir/ritonavir may result in some benefit, particu-
larly in the light of confirmed artemisinin resistance
having spread from western Cambodia across mainland
South East Asia, from southern Vietnam to western
Myanmar [31–33].
Two previous studies in American and Ugandan adults
have examined the interaction of lopinavir-based anti-
retroviral therapy and artemether-lumefantrine, using
different methods to our study [25, 29]. Due to concerns
about substantially elevated lumefantrine concentrations
we included a single-dose phase, which then determined
the dosing regimen used for our second six-dose phase.
Our single-dose phase found a doubling of the lumefan-
trine exposure, which was similar to the result found in
a single-dose study of Ugandan malaria-negative, HIV-
infected patients on lopinavir-based antiretroviral ther-
apy, and in a healthy volunteer, six-dose study conducted
in the United States (Table 6). In the six-dose phase of
our trial, the lumefantrine exposures in our ARV-naïve
group were similar to those in American healthy volun-
teers (445 vs. 456 ug.h/mL respectively). However, our
patients on lopinavir-based antiretroviral therapy had
1.6-fold higher maximal concentrations and 2.3-fold
higher exposures than the healthy volunteers on lopina-
vir in the American study. Hoglund et al. (2015) who
reanalysed the pharmacokinetic data from the single-
dose study in Ugandan HIV-infected, malaria-negative
adults [30] using non-linear mixed-effect modelling, also
found that lopinavir-ritonavir increased lumefantrine ex-
posure by 439 %, largely explained by its clearance being
decreased by 62 %.
To minimise any safety risks, and to obtain an esti-
mate of the effect size of the pharmacokinetic drug-
drug interaction without confounding by any malaria
disease effect, neither our study nor both studies in
adults cited above included malaria patients [25, 29].
Thus, we could not determine whether increased lume-
fantrine exposure improved antimalarial therapeutic
efficacy. Previous studies in malaria patients have
shown that the day-7 lumefantrine concentration is the
most important single concentration measure in terms
of its correlation with the area under the concentration
time curve and its association with treatment response
[4, 11, 34]. In a large pooled analysis in 2528 patients,
treatment failure was associated with low day-7 lume-
fantrine concentrations; the risk of recrudescence de-
creased by 36 % (HR 0.64 (0.55 to 0.74) <0.001) and the
risk of reinfection decreased by 21 % (HR 0.79 (0.72 to
0.87) <0.001) with a doubling of lumefantrine concen-
trations [11]. Thus the marked increases in lumefan-
trine concentration observed in our lopinavir group
would be expected to reduce their risk of treatment
failure. This has been evaluated in malaria and HIV
co-infected children, but not yet in co-infected
adults [35, 36]. In co-infected Ugandan children
under six-years of age (median age 2.9 years), recur-
rent malaria and malaria incidence were lower fol-
lowing artemether-lumefantrine treatment in those
on lopinavir-based ART than in those on non-
nucleoside reverse transcriptase inhibitor (NNRTI)-
based ART. The Ugandan paediatric lopinavir group
had elevated day-7 lumefantrine concentrations of
388 ng/mL and day-7 concentrations above 300 ng/mL
Table 5 Treatment Emergent Adverse Events by treament group, causality and intensity (Continued)
Eye disorders
Uveitis 1
Psychiatric disorders
Alcoholic hangover
Self-induced vomiting 1
Metabolism and nutrition disorders
Hypercholesterolaemia
Oedema peripheral 1
Injury, poisoning and procedural complications
Skin wounds 1
TOTAL 15 0 19 1 12 0 27 3
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Table 6 Drug interaction studies between artemether-lumefantrine and lopinavir/ritonavir, showing median lumefantrine, artemether and dihydroartemisinin pharmacokinetic
parameters with and without lopinavir/ritonavir
Study
(Reference)
Population Comparator groups Artemether-
lumefantrine
dose
Concomitant
fat intake
Samples per
participant
(matrix)
Lumefantrine Artemether Dihydro-artemisinin
AUC Cmax Day 7 AUC Cmax AUC Cmax
Kredo HIV infected,
malaria negative
adults
Parallel: Lopinavir
based ART vs.
ARV-naïve
Single dose
(Phase 1)
Yes 22 (Plasma) Single dose:
AUC(0-inf) 1852
vs. 1133 μg.h/mL
5.26 vs.
2.50 μg/mL
NA NA NA NA NA
Standard 6-dose
regimen (Phase 2)
Yes 33 (Plasma) AUC(0-inf) 2477
vs. 445 μg.h/mL
28.15 vs
8.76 μg/mL
3170 vs.
336 ng/mL
AUC(0-8h) 220
vs. 151 ng.h/mL
85.8 vs.
59.7 ng/mL
AUC(0-8h) 283.6
vs. 123.8 ng.h/mL
77.5 vs.
42.2 ng/mL
Byakika-
Kibwika25
HIV infected,
malaria negative
adults
Parallel: Lopinavir
based ART vs.
ARV- naïve
Single dose Yes 9 (Plasma) AUC(0-inf) 267
vs. 47 μg.h/mL
7.10 vs.
2.53 μg/mL
NA AUC(0-inf) 162
vs 271 ng.h/mL
56 vs
112 ng/mL
AUC(0-inf) 180
vs 217 ng.h/mL
73 vs
66 ng/mL
German29 Healthy adult
volunteers
Cross-over: Artemether
lumefantrine given
before and after 26
days Lopinavir-based
ART
Standard 6 dose
regimen
Yes 10 (Plasma) AUC(0–264) 1073
vs 456
17.4 vs
12.5 μg/mL
NA AUC(0-inf) 40.5
vs. 62.0 ng.h/mL
11.2 vs
14.3 ng/mL
AUC(0-inf) 109
vs 198 ng.h/mL
37.3 vs
58.8 ng/mL
Achan35 HIV-infected
children with
malaria on ART
Parallel: Lopinavir-
based ART vs. NRTI-
based antiretrovirals
Standard 6 dose
regimen
Not
reported
1
(Capillary blood)
NA NA Lopinavir:
926 ng/mL
NA NA NA NA
Nevirapine:
388 ng/mL
Efavirenz:
97 ng/mL
Kredo
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were associated with a significantly decreased risk of mal-
aria recurrence within 63 days.
Previous studies show that the absorption of lumefan-
trine was close to saturated at the currently recommended
dose [37], which is a major obstacle for optimising dosage
recommendations for patient sub-groups who do not
achieve target concentrations with the currently recom-
mended dosage regimens [12]. However, we showed that
an increase in lumefantrine mg/kg dose was associated
with a significant increase in the lumefantrine Cmax and
AUC(0-inf), in the lopinavir group but not the ARV-naïve
group. Lumefantrine is N-debutylated by CYP3A4, but
desbutyl-lumefantrine represents approximately 0.3–1 %
of the parent exposure [12] suggesting inhibition of intes-
tinal CYP3A4 and possibly other transporters as a mech-
anism. These findings may contribute towards a better
understanding of the mechanism underlying the non-
linear relationship between lumefantrine dose and bio-
availability, and of interventions that could be studied in
key target populations in whom lumefantrine is currently
sub-optimally dosed.
Conclusions
Despite markedly higher lumefantrine exposure, inten-
sive monitoring in our relatively small study raised no
safety concerns associated with using the current recom-
mended six-dose regimen of artemether-lumefantrine in
HIV-infected adult patients receiving lopinavir-based
antiretroviral therapy. Elevated lumefantrine concentra-
tions have been shown to reduce the risk of treatment
failure as reported previously in malaria patients of all
ages [4, 11], and in malaria and HIV co-infected chil-
dren [35, 36]. Further evidence in adults co-infected with
malaria and HIV is required to substantiate these results.
Our ARV-naïve patients confirmed previous studies’
findings that lumefantrine absorption is close to satur-
ation with currently recommended doses, but this dose-
limited absorption was overcome in those on lopinavir-
based ART.
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